Intrinsic Value of S&P & Nasdaq Contact Us

Danaher Corporation DHR-PB NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
62/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Danaher Corporation (DHR-PB) generated $6.42B in operating cash flow for fiscal year 2025. After capital expenditures of $1.16B, free cash flow was $5.26B.

Free cash flow margin was 21.4% of revenue. Cash conversion ratio was 1.78x, indicating earnings are backed by cash.

The company returned $878M in dividends and $3.09B in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (92/100, Pass) — $5.26B (21.4% FCF margin) supports a durable competitive advantage
  • INCOME (55/100) — Cash conversion ratio was 1.78x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 62/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
62/100
SG Score
View full scorecard →
VALUE
15/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
55/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
92/100
Proven by this page
GROWTH
15/100
→ Income
~
INCOME
55/100
→ Income
Danaher Corporation Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $6.42B$6.42B$6.69B$7.16B$8.52B
Capital Expenditure $-1.16B$-1.16B$-1.39B$-1.38B$-1.15B
Free Cash Flow $5.26B$5.26B$5.3B$5.78B$7.37B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message